

poverty metric	model	r^2	RMSE
whole country			
DHS WI	CDR-RS	0.76	0.394
	CDR	0.64	0.483
	RS	0.74	0.413
PPI	CDR-RS	0.25	57.907
	CDR	0.23	58.562
	RS	0.32	57.439
income	CDR-RS	0.27	105.465
	CDR	0.24	107.155
	RS	0.22	108.682
urban			
DHS WI	CDR-RS	0.78	0.424
	CDR	0.70	0.552
	RS	0.71	0.433
PPI	CDR-RS	0.00	60.128
	CDR	0.03	60.935
	RS	0.00	60.384
income	CDR-RS	0.15	168.452
	CDR	0.15	172.738
	RS	0.05	176.705
rural			
DHS WI	CDR-RS	0.66	0.402
	CDR	0.50	0.483
	RS	0.62	0.427
PPI	CDR-RS	0.18	57.397
	CDR	0.17	57.991
	RS	0.21	57.162
income	CDR-RS	0.14	81.979
	CDR	0.13	82.773
	RS	0.23	76.527

text	text	text	text
text			
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text

text	text	text	text
	text	text	text
	text	text	text
text			
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text			
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text

Clinical parameters	WWOX intensity		Total	p value
	Low (Negative/Weak)	High (Moderate/Strong)		
Grade (GOG)				
I	4 (23%)	13 (77%)	17	p = 0.707
2	9 (33%)	18 (67%)	27	
3	107 (33%)	215 (67%)	322	
Stage (FIGO)				
I	7 (23%)	24 (77%)	31	p = 0.007
II	8 (29%)	20 (71%)	28	
III	74 (31%)	168 (69%)	242	
IV	31 (48%)	34 (52%)	65	
Relapse				
No	31 (32%)	66 (68%)	97	p = 0.09
Yes	61 (31%)	137 (69%)	198	
Progressive disease	27 (46%)	32 (54%)	59	
ER				
Negative	22 (25%)	66 (75%)	88	p = 0.984
Positive	59 (25%)	176 (75%)	235	
PR				
Negative	70 (29%)	170 (71%)	240	p = 0.00
Positive	12 (14%)	71 (86%)	83	

text	text	text	text	text
	text	text		
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	

	Offspring Genotype		ANOVA
	CC	CT	
Birthweight (gm)	3425 ± 490 (n = 408)	3535 ± 495 (n = 126)	P = 0.007
Cord IGF-II (ng/dl)	262 ± 80 (n = 125)	266 ± 98 (n = 36)	P = 0.8

	text		text
	text	text	
text	text	text	text
	text	text	
text	text	text	text
	text	text	

Main cellular process	Modulated pathways	P value		Genes in pathway		
		+ PMN	- PMN	Expressed		total
				+ PMN	- PMN	
Cell cycle	Role of APC in cell cycle regulation	1.040E-09	8.149E-08	15	12	32
	Chromosome condensation in prometaphase	4.131E-06	8.392E-11	9	12	20
	The metaphase checkpoint	4.423E-06	1.474E-04	12	9	36
	Spindle assembly and chromosome separation	3.170E-04	1.937E-03	9	7	32
	Start of DNA replication in early S phase	1.284E-03	3.115E-02	8	5	31
	Initiation of mitosis	1.544E-03	2.483E-03	7	6	25
	Sister chromatid cohesion	1.530E-02		5		21
	Transition and termination of DNA replication		1.523E-02		5	26
	Role of Nek in cell cycle regulation		2.390E-02		5	29
	Nucleocytoplasmic transport of CDK/Cyclins		4.386E-02		3	14
Immune response	Alternative complement pathway	4.539E-07	2.737E-02	12	5	30
	Fc gamma R-mediated phagocytosis	1.606E-03	9.058E-03	8	6	32
	Antigen presentation by MHC class II	6.046E-03	2.644E-03	4	4	11
	Classic complement pathway	1.517E-05		12		40
	Antiviral actions of Interferons	2.431E-04		9		31
	CCR3 signalling	8.728E-04		12		59
	Lectin induced complement pathway	1.251E-03		9		38
	Lipoxin inhibitory action on Superoxide production	1.544E-03	2.483E-03	7	6	25
	IFN alpha/beta signalling pathway	6.214E-03		6		24
	IL-10 signalling pathway	2.245E-02		5		23
Oxidative stress	Antigen presentation by MHC class I	3.675E-02		5		26
	Transcription regulation of granulocyte development		3.115E-02		5	31
	ROS production	8.932E-04	4.113E-02	7	4	23
Apoptosis	Inhibition of ROS induced apoptosis	3.675E-02		5		26
G protein signalling	Rac2 regulation pathway	4.957E-03	4.113E-02	6	4	23
	RAC1 in cellular process	1.361E-02		6		28
Cytoskeleton remodelling	Regulation of actin cytoskeleton by Rho GTPases	8.972E-03			5	23
	Alpha-1A adrenergic receptor-dependent inhibition of PI3K	2.887E-02			3	12
Metabolic process	Lipoprotein metabolism I. Chylomicron, VLDL and LDL metabolism	1.630E-02	9.007E-07	3	6	8
	Lipoprotein metabolism II. HDL metabolism	1.630E-02	9.007E-07	3	6	8
	G-alpha(q) regulation of lipid metabolism	2.245E-02		5		23
	Urea cycle	3.675E-02		5		26
	LDL metabolism during development of fatty streak lesion	1.870E-02			2	4

text	text	text	text	text	text	text
				text		text
		text	text	text	text	
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
	text		text		text	text
	text		text		text	text

	text		text		text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text	text	text	text	text	text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text		text		text	text
text	text	text	text	text	text	text
text	text	text		text		text
text	text	text	text	text	text	text
	text	text		text		text
text	text	text			text	text
	text	text			text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
	text	text		text		text
	text	text			text	text

Presenting complaints	N (% of total sample n = 259288)	*Pulse	*BP	* T°C	*GCS	*RR	*SpO ₂
Fever	31554 (12.2)	9964 (31.6)	9645 (30.6)	12528 (39.7)	1170 (3.7)	3797 (12.0)	1288 (4.1)
Injury (non-head/face/neck)	29695 (11.4)	2767 (9.3)	3200 (10.8)	2583 (8.7)	441 (1.5)	2267 (7.6)	1437 (4.8)
Abdominal pain	23170 (8.9)	5886 (25.4)	5986 (25.8)	4516 (19.5)	311 (1.3)	1520 (6.6)	732 (3.2)
Chest pain	20130 (7.8)	8630 (42.9)	9076 (45.1)	7008 (34.8)	1371 (6.8)	5157 (25.6)	1409 (7.0)
Injury (Head/face/neck)	13309 (5.0)	1769 (13.3)	2064 (15.5)	1669 (12.5)	394 (3.0)	1418 (10.7)	852 (6.4)
Vomiting	10629 (4.1)	3135 (29.5)	3372 (31.7)	2508 (23.6)	211 (2.0)	1098 (10.3)	606 (5.7)
Headache	9516 (3.7)	3267 (34.3)	3706 (38.9)	2779 (29.2)	286 (3.0)	887 (9.3)	271 (2.8)
Shortness of breath	8548 (3.3)	2711 (31.7)	3087 (36.1)	1936 (22.6)	219 (2.6)	1436 (16.8)	611 (7.2)
Back pain	8239 (3.2)	1557 (18.9)	1597 (19.4)	1392 (16.9)	39 (0.5)	368 (4.5)	169 (2.1)
Diarrhea	5954 (2.3)	1835 (30.8)	1916 (32.2)	1588 (26.7)	108 (1.8)	608 (10.2)	244 (4.1)
Total	160744 (62.0)	41521 (25.8)	43649 (27.8)	38507 (24.0)	4550 (2.8)	18556 (11.5)	7619 (4.7)

[illegible]

		text					
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text

	MOD		Percent Positive Area		Percent Positive Nuclei	
	CaP	BP	CaP	BP	CaP	BP
AA	0.34 ± 0.09	0.32 ± 0.06	0.37 ± 0.20	0.45 ± 0.22	0.25 ± 0.15	0.28 ± 0.18
CA	0.25 ± 0.06	0.30 ± 0.08	0.38 ± 0.25	0.35 ± 0.18	0.26 ± 0.12	0.25 ± 0.11
	P < 0.05	P > 0.05	P > 0.05	P > 0.05	P > 0.05	P > 0.05

	text		text		text	
	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text

Variable	Hazard ratio	95 % CI	p value*
Age (median)			0.716
≤69	1.000		
>69	0.839	0.310–2.268	
Gender			0.142
Male	1.000		
Female	0.426	0.152–1.190	
Type of surgery			0.010
Low anterior resection	1.000		
Abdominoperineal resection	3.140	0.919–10.725	
Tumor location			0.710
Upper rectum	1.000		
Middle rectum	1.267	0.381–4.213	
Low rectum	1.716	0.419–7.026	
Grade of differentiation			0.936
G1	1.000		
G2	1.933	0.416–3.423	
G3	1.119	0.137–9.137	
Histologic type			0.299
Adenocarcinoma	1.000		
Adenocarcinoma with mucinous features	0.381	0.096–1.514	
Depth of tumor invasion			0.925
T3	1.000		
T4a	0.919	0.316–2.673	
T4b	0.745	0.172–3.223	
Tumor size			0.329
≤4 cm	1.000		
>4 cm	0.594	0.214–1.651	

text	text	text	text
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text	text	text	
text			text

text	text	text	text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text	text	text	text

	Sulodexide				Control			
	Abdominal pain upper	Nausea	Vomiting	Allergy	Abdominal pain upper	Nausea	Vomiting	Allergy
Andreozzi et al., 2015	6	0	0	4	5	4	5	1
Cirujeda and Granado, 2006*	0	0	0	1	0	0	0	3
Erichi et al., 2004	0	0	0	0	0	0	0	0
Total		11				18		

	text				text			
	text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text	text
text	text	text	text	text	text	text	text	text
text	text			text				

Side effects	Number of patients with toxicity (%)				
	Grade 1	Grade 2	Grade 3	Grade 4	All grades
<i>Hematological</i>					
Anemia	4 (9.5%)	0	0	0	4 (9.6)
Leucopenia	4 (9.5%)	2 (4.8%)	0	0	6 (14.2%)
Neutropenia	1 (2.4%)	1 (2.4%)	2 (4.8%)	0	4 (9.6%)
Thrombocytopenia	2(4.8%)	2 (4.8%)	0	0	4 (9.6%)
<i>Non-hematological</i>					
Nausea/Vomiting	5 (11.9%)	11 (26.2%)	0	0	16 (38.1%)
Mucositis	7 (16.7%)	5 (11.9%)	1 (2.4%)	0	13 (31.0%)
Neurotoxicity	8 (19.0%)	5 (11.9%)	1 (2.4%)	0	14 (33.3%)
Diarrhoea	8 (19.0%)	7 (16.6%)	2 (4.8%)	0	17 (40.4%)
Asthenia	15 (35.7%)	11 (26.2%)	3 (7.1%)	0	29 (69.0%)
Hyperbilirubinemia	1 (2.4%)	3 (7.1%)	0	0	4 (9.5%)
Anorexia	5 (11.9%)	3 (7.1%)	0	0	8 (19.0%)

text	text				
	text	text	text	text	text
text					
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text					
text	text	text	text	text	text

text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text

n)	Distance (mi)	Percent Fuel Savings		
		Improved Speed	Decreased Accel	Eliminated Stops
	1.3	5.9%	9.5%	29.2%
	11.2	2.4%	0.1%	9.5%
	58.7	8.5%	1.3%	8.5%
	57.8	21.7%	0.3%	2.7%
	173.9	58.1%	1.6%	2.1%

			text			
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text

Response (percent) to effects dimension						
Domain	Attribute (effect on)	Never Visited Dentist n = 79			Last visit >1 year ago n = 185	Last visit within 1 year n = 92
		Very bad/Bad	None	Very good/Good	Very good/Good	Very good/Good
Physical	Eating	6.2	15.0	78.8	73.7	60.9 ^b
	Appearance	3.8	15.0	81.2	71.0	69.6 ^c
	Speech	2.5	17.5	80.0	68.3	65.2 ^b
	General Health	3.8	20.0	76.2	75.8	67.4
	Breath	7.5	23.8	68.7	66.1	53.3
	Comfort/Relaxation	2.5	35.0	62.5	62.4	51.1 ^c
Psychological	Sleep	5.0	27.5	67.5	53.2	56.5
	Confidence	10.0	15.0	75.0	55.4	69.6
	Worry	5.0	33.8	61.2	53.2	46.7 ^b
	Mood	8.8	33.7	57.5	48.4	42.4 ^b
	Personality	7.5	23.8	68.7	61.3	57.6
Social	Social life	7.5	25.0	67.5	67.2	62.0
	Romantic Relationship	7.5	33.8	58.7	64.0	58.7
	Smiling	7.5	21.2	71.2	69.4	70.7
	Work	5.0	38.8	56.2	46.2	43.5 ^c
	Finance	0.0	53.8	46.2	34.4	32.6 ^b

		text				
		text			text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text

Observed Unordered Genotypes/Number of A Alleles in Pool j True Unordered Genotype AABB					
α	BBBB/ 0	ABBB/ 1	AABB/ 2	AAAB/ 3	AAAA/ 4
1	0.063	0.250	0.375	0.250	0.063
5	0.0002	0.131	0.737	0.131	0.0002
25	0.000	0.006	0.988	0.006	0.000
125	0.000	0.000	1.000	0.000	0.000

	text				
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text

MALE						
Thyroid condition	Exposed group with dose detected (G1)		Exposed group with doses = 0 (G2)		Not Exposed (G3)	
	N	%	N	%	N	%
Incidentalomas	15	11,3	8	10,4	17	9,3
Nodules (single or multiple)	5	3,8	7	9,1	34	18,7
Thyroiditis	6	4,5	3	3,9	6	3,3
Healthy	107	80,5	59	76,6	125	68,7
Total	133	100,0	77	100,0	182	100,0
FEMALE						
Thyroid condition	Exposed group with dose detected (G1)		Exposed group with doses = 0 (G2)		Not Exposed (G3)	
	N	%	N	%	N	%
Incidentalomas	3	9,7%	7	16,7%	26	13,2
Nodules (single or multiple)	1	3,2%	4	9,5%	40	20,3
Thyroiditis	2	6,5%	3	7,1%	17	8,6
Healthy	25	80,6%	28	66,7%	114	57,9
Total	31	100,0%	42	100,0%	197	100,0

	text					
text	text		text		text	
	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
text	text	text	text	text	text	text
	text					
text	text		text		text	

text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text			
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text

text	text	text	text
text	text	text	text
text	text	text	text
text			
text	text	text	text
text	text	text	text
text	text	text	text